Filing Flows › Aktis Oncology (AKTS) › Stock forecast & fair value
Aktis Oncology (AKTS) stock forecast and price target
Aktis Oncology (AKTS) trades at $15.82. 8 analysts' median price target is $35.00 (+121%), from $33.00 to $40.00.
Aktis Oncology's latest quarter
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for AKTS stock?
The median of 8 analysts' 12-month targets is $35.00, +121% from $15.82; the range is $33.00 to $40.00. The average rating is none.
Does Aktis Oncology usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is AKTS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.